logo header
                                               DoReMi's 3rd competitive call is closed Login

2nd COMPETITIVE CALL

 

hmscholar

Information about DoReMi competitive call

The substantial scientific challenges related to the low dose risk research require a multidisciplinary approach and new competencies and capacities. Therefore, a large portion of DoReMi Flexibility budget has been reserved to organizes competitive calls for proposals to identify new partners to answer to these emerging needs for integrated research.

The first competitive call was organized in 2010 and as a result, ten new beneficiaries joined the consortium.


2nd Competitive call for additional project partner

The European Network of Excellence DoReMi addresses the health risks of low doses of ionising radiation such as those that are encountered in the environment, occupationally and in the course of medical diagnostic procedures.

Call identifier: DoReMi-2012
Publication Date: 16 February 2012
Budget: € 1 400 000 (EC contribution)
Deadline: The call closed on 18 April 2012, 17h00 (Brussels time)

The 2nd competitive call process has been completed and ten new organizations have joined DoReMi from January 2013 onwards. »» More information about new partners »»

DoReMi-2012 Call announcement is available below.
  »
Printable version as well as other call-related documentation are available at the bottom of this page:

ANNOUNCEMENT OF A COMPETITIVE CALL FOR ADDITIONAL PROJECT PARTNERS
The following project currently active in the Seventh Framework programme of the European Atomic Energy Community for research, technological development and demonstration activities contributing to the creation of the European research area and to innovation (2007-2011) requires the participation of new project partners to carry out certain tasks within the project. Please note that the Seventh Framework Programme offers part-funding not full-funding of research activities.

Project grant agreement number: 249689
Project acronym: DoReMi
Project full name: Low Dose Research towards Multidisciplinary Integration
Instrument type: Network of excellence

Brief summary of task(s) requested:
To address the health risks of low doses of ionising radiation such as those that are encountered in the environment, occupationally and in the course of medical diagnostic procedures (these are described further in the High Level and Expert Group Report on Low Dose Risk (www.hleg.de) and the DoReMi Transitional Research Agenda (prepared in July 2010) and TRA Statement (prepared in September 2011), the DoReMi consortium is seeking new expertise, infrastructures and platforms for analyses related to the 5 tasks described below. DoReMi defines low doses as those of 100 mGy or less and medium doses as 0.1 Gy - 1 Gy for low LET radiations. Low and medium dose rates are defined as 0.1 Gy/h or less for low LET radiations. For high-LET radiations, dose and dose-rates of interest are lower, e.g. for alpha radiation by an order of magnitude.

A detailed account of the Tasks to be carried out:

Task 1: Studies which will lead to better understanding of the underlying mechanisms of radiation-induced optical changes e.g. lens opacities at low doses, both in animals and humans.

Submitters should demonstrate competencies in at least one of the following areas: clinical ophthalmology, eye lens biology, eye lens dosimetry, experimental models used in ophthalmology, and devices/methods that contribute to the diagnosis of eye lens opacity. The submitted projects should address at least one of the questions described in the following 6 issues:

  1. The establishment of over-life dose-response curves at low doses in animal models. The aim of work addressing this task will be to determine whether a dose threshold exists or not. Doses between 0 and 2 Gy should be considered, and a focus on accurate dosimetry is highly desirable. Experimental designs should address factors involved in cataract formation, with a specific focus on gender and genetic background effects (see issue 5).
  2. The design of more appropriate experimental models (in vivo, in vitro, ex vivo). For animal models, the effects of different methods of irradiation (e.g. head or eyes, single eye or both eyes), radiation sources (radiation quality and LET), high and low dose rates and different irradiation schedules (e.g. single vs. fractionated dose) should be considered. Similarly, effects should be compared in irradiated lens cells (e.g. lens explants, primary lens epithelial cell culture) or in intact, but isolated lenses.
  3. The identification of the suitable cohorts and types radiation for epidemiological and clinical studies. There is a need for clinical and epidemiological studies with precise dosimetry, a quantitative determination of lens opacities (including determination of visual acuity), and studies of appropriate size for powerful statistics.
  4. The collection of quantitative data on lens opacities using techniques/devices like Scheimpflug camera or DLS device. Related to issue 3, there is a need to compare different methods for detecting lens opacities in humans. It is crucial to determine which method is best and most appropriate for epidemiological purposes (in order to omit observer bias) and also to move towards quantitative rather than qualitative data for assessment of cataract type and severity.
  5. To increase understanding of the role played by factors affecting cataract development, including genetic background, gender, strain, age at exposure. This is a cross-sectional objective; the mentioned parameters need to be addressed both in animal and human (epidemiological) studies (see issues 1 and 3).
  6. The identification of early predictive markers and clinical endpoints. Based upon biochemical and cell-biological approaches, work addressing this task should compare different biological endpoints related to radiation-induced cataract formation to develop finally early biomarkers of clinical relevance.


Task 2: Mechanistic insights into epigenetic and genetic regulatory processes and their role in cancer and non–cancer diseases

There is growing realisation that cell and organism phenotypes can be altered by epigenetic modification of gene expression as well as by direct mutational changes. Such epigenetic modifications include DNA methylation, histone modification and modulation by microRNAs. Epigenetic changes have been observed in human diseases and likely contribute to disease development. Furthermore, there is evidence to suggest that radiation exposure of cells and experimental organisms can lead to epigenetic modification of gene expression. In addition, DNA damage responses processes play an important role in radiation-induced cancer risk. The current DoReMi consortium lacks expertise in epigenetic mechanisms and techniques as well as in the characterisation of initial DNA damage and associated response regulatory processes. This task therefore calls for competence in epigenetics and in molecular biology, biochemistry and biophysics of specific DNA damage signalling and regulation pathways. Proposals should address one or more of the following issues:

  1. What is the dose dependency for radiation-induced epigenetic modification of gene expression, particularly at low doses and dose rates and which epigenetic mechanisms are affected by ionising radiation?
  2. How stable are such changes?
  3. Do radiation-induced epigenetic changes contribute to radiation-associated disease (cancer/non cancer)?
  4. Are there epigenetic changes that affect individual sensitivity to radiation – associated diseases?
  5. Analysis of the pathways involved in DNA damage signalling, DNA repair and cell cycle control mechanisms depending on radiation quality, dose and response or dose rate: involvement of genetic and/or epigenetic control mechanisms.
  6. Analysis of interactions between DNA repair pathways at low doses: molecular switches
    and regulatory control mechanisms towards the use of alternative repair mechanisms or components depending on lesion complexity, radiation quality, dose or dose rate.


Task 3: Integrated studies of cancer risk following exposure to internal emitters

In March 2011 DoReMi held a workshop to review the prospects for studies to improve the estimation of cancer risk following internal radiation exposures. A consensus view emerged that the estimation of cancer risks associated with internal radiation could be improved by integrated studies drawing on epidemiology, radiation dosimetry and experimental biology. Studies considering nuclear industry workers, uranium miners and populations exposed as a consequence of the Chernobyl accident or of releases from the Mayak plant (Techa river residents) were considered to be those most likely to yield useful data in the near term. Combination of the following components was judged to be of particular value:

  1. epidemiological follow-up studies of populations
  2. consideration of the chemical form of the exposure
  3. careful attention to radiation dosimetric issues
  4. human biomarker studies
  5. appropriate experimental investigations in animals or cells/tissues.

This task therefore calls for applications for integrated studies to improve cancer risk estimation following internal radiation exposure.


Task 4: Novel approaches

The DoReMi consortium is looking for expertise and platforms for novel approaches that would be useful in the understanding and evaluation of health risks from exposures to low doses of radiation. Any proposed approach should be in line of DoReMi objectives and TRA.


Task 5: Provision of infrastructures

Provisions of infrastructures allowing radiation quality studies below 20MeV/u and above 100 MeV/u and/or microbeam(s): Improving the access and the realization of radiobiology studies at specific irradiation facilities. The aim would be to promote the assessment of local damage and radiation quality effects on several biological endpoints (DNA lesions and repair, oxidative stress, cell death, cell transformation,...) in various cellular models.

The submitted projects will propose: Microbeam irradiation facilities for individual cells using sparse radiation (photons or particles) with a very good accuracy and dosimetry (follow-up of direct or delayed bystander effects)
                            OR /AND
The exposure to accelerated particles in a wide range of energies, especially those rarely available: below 20 MeV/u and above 100 MeV/u
In addition it would be necessary to have:

  • Involvement of local research team of strong scientific background in the field
  • A significant access to the facility in order to repeat experiments

Expected duration of participation in project: From January 2013 to December 2015, depending on the complexity of the task.

Total Commission funding available for the tasks: The proposals addressing each Task can be submitted by an individual organisation or a small consortium consisting of max. 2 partners. A maximum of 1,4M€ is available for the Call, with an indicative amount of up to 300 000€ for each task.

Language in which proposal should be submitted: English


DoReMi 2nd competitive call documents (printable version):

  • Competitive Call Announcement
  • Guide for applicants
  • Proposal template (extract from Guide for applicants)
  • DoReMi Consortium Agreement for 2nd competitive call
  • TRA
  • TRA Statement

Get support :

Mail address for further information (Project coordinator): doremi@stuk.fi
To receive information about DoReMi, please subscribe our Newsletter: DoReMi Newsletter subscribers.